11.3 Return, Reuse, and Take-Back

Why return and reuse are Competency 2.4

Quick Answer: Do not put a patient’s returned community vial back into stock. CGS § 20-576a and RCSA §§ 20-576a-1 to 20-576a-7 let a DCP-registered authorized collector (who also holds DEA collector registration under 21 CFR 1317) accept unused drugs, including controlled substances, into a one-way receptacle for destruction — not redispensing. Staff shall not handle, count, sort, or inventory what the patient brings. CGS § 20-621 is the narrow hospital/nursing-home parenteral restock exception (unopened, tamper-evident, not a controlled substance). A reverse distributor destroys take-back liners and, separately, the pharmacy’s own expired inventory. Those are not the same event.

NABP Area 2.4 tests whether you can tell reuse, patient-requested disposal, pharmacy-inventory destruction, and DEA take-back apart. Connecticut wrote the take-back program as destruction. Candidates who treat a drop box as a donation shelf miss the leaf.

Community rule: no patient-return restock

Once a dispensed drug has been in a patient’s possession, a Connecticut community pharmacy does not return it to the fast-mover bay. The reasons are quality and custody, not manners:

• Contamination and storage history are unknown. Heat, moisture, and substitution can make the article adulterated under the FDCA even if the cap is still on.
• Chain of custody broke when the bag left the pharmacy. You cannot prove the tablets in the vial are the tablets you dispensed.
• Misbranding risk follows any relabel onto a different patient.

A sealed manufacturer bottle does not create a community exception just because the foil looks intact. “The patient never opened it” is still a patient-controlled article. Do not invent a Connecticut unused-drug donation-to-stock program inside Chapter 400j; § 20-576a is titled acceptance and disposal, and the regulations send the inner liner to a reverse distributor for destruction.

Distinguish a true patient return from product that never left the pharmacy. CGS § 20-602(c) lets a clerk, under pharmacist supervision, return to stock product used to fill a prescription but not sold. That is the will-call bag the patient never picked up — still in pharmacy custody, never dispensed into the patient’s hands. It is not permission to restock a vial that came back from a car glove box.

The institutional exception — CGS § 20-621

A pharmacist practicing in a hospital pharmacy or nursing-home pharmacy may relabel and dispense to a registered inpatient parenteral medication, except controlled substances, that was dispensed for another registered patient by a licensed pharmacy if all of the following are true:

1. The original medication order for the drug is discontinued.
2. The medication is in an unopened tamper-evident package.
3. The medication is not expired.
4. The original patient is not charged.
5. Upon receipt by the facility, it is processed through the hospital’s or nursing home’s pharmacy.

That list is conjunctive. A New Haven hospital that credits Patient A, runs an unopened tamper-evident cefazolin bag through the pharmacy, and relabels it for Patient B after A’s order is stopped is inside § 20-621. A community pharmacist who “does the same thing” with a patient’s returned insulin pen is not. Controlled-substance parenteral products are outside this exception even in the institution.

Take-back is destruction — CGS § 20-576a and RCSA 20-576a

CGS § 20-576a directed the Commissioner of Consumer Protection, with the Commission of Pharmacy, to adopt regulations allowing not more than fifty retail pharmacy locations in the first year and not more than an additional fifty each year thereafter to accept and dispose of unused prescription drugs. The regulations must comply with federal collector law, establish tracking, monitoring, and security, specify where in the pharmacy drugs may be accepted and stored, and — after consulting DEEP — ensure secure removal and destruction, including optional agreements with law enforcement.

RCSA §§ 20-576a-1 to 20-576a-7 (effective July 8, 2019) are those regulations. High-yield operational rules:

• An authorized collector is a retail pharmacy licensed under § 20-594, authorized to handle controlled substances, with active DEA collector registration and a DCP collector registration. DCP registration renews annually on or before January 31. DCP inspects the premises, receptacle, and written procedures before collection starts.
• The collection receptacle is a secured, one-way box for ultimate users (and a person lawfully disposing of a decedent’s drugs) to deposit unused or expired drugs, including controlled substances and legend and non-legend drugs.
• The pharmacy shall not put its own inventory or stock in the receptacle (§ 20-576a-2(g)).
• No employee, including authorized employees, shall handle, count, sort, or inventory drugs the ultimate user brings for deposit (§ 20-576a-2(i)). The patient places the drugs in the box. Staff do not pour a returned oxycodone vial onto a tray “to log the CII.”
• The collector shall not run a mail-back program that receives drugs by mail (21 CFR 1317.70 overlay in § 20-576a-2(f)), and shall not host a take-back event inside the same building as the receptacle (§ 20-576a-2(e)).
• The receptacle sits in immediate proximity of CS storage, visible to an authorized employee, accepts deposits only while the pharmacy is open and an authorized employee is present, and uses two different-key locks on the liner, operated by two authorized employees. If fill level must be checked, two authorized employees do it and one must be a Connecticut licensed pharmacist; overfill imminent means lock the one-way slot and start disposal within 48 hours.
• Video monitors access points and liner sealing with at least 14 days of storage. Loss, theft, serious damage, or destruction of the receptacle or contents is reported to the Drug Control Division director within 72 hours. Collector records stay on site three years.
• Confidentiality of ultimate users who use the box is required (§ 20-576a-2(h)) — take-back is not a second counseling window for naming the drug in the waiting room.

Reverse distributor versus patient-requested disposal

RCSA § 20-576a-5 is liner disposal, not restock:

• The reverse distributor (or law enforcement under an agreement) must be present and ready to receive the liner.
• Two authorized employees, one a Connecticut licensed pharmacist, remove the rigid container and liner together, immediately seal the liner, replace it, and tape the rigid container with no outer marking of the contents.
• The sealed unit goes to the registered reverse distributor; no materials in the liner are removed, counted, sorted, or handled; no on-site destruction of liner contents by the pharmacy.
• Inner liners have a permanent unique identification number and are not reused.

RCSA § 20-576a-6 registers reverse distributors with DCP (renew January 31), forbids opening the rigid container before destruction unless the commissioner orders it, requires two reverse-distributor employees to witness destruction, and requires a 72-hour loss/theft report to Drug Control. Reverse distributors must also follow 21 CFR 1317 and laws on salvaging — they are not a pipeline to put take-back drugs back into the selling pharmacy’s stock.

Keep three destruction pathways separate in your head:

DEA take-back events (21 CFR 1317.65) are typically law-enforcement hosted. A Connecticut authorized collector does not run one inside the same building as its receptacle. National DEA Take Back Days are not a community restock fair.

Patients who simply want to get rid of a bottle, at a pharmacy that is not an authorized collector, should be pointed to a collector, a law-enforcement drop box, or — for opioids — the personal deactivation information CGS § 20-633m permits a pharmacist to provide at dispensing (DMHAS website; does not apply while the patient is in a facility). That statute is information, not a mandate to take the bottle over the counter into the trash.

CGS § 20-636 adds two consumer-facing duties that travel with this leaf: a conspicuous sign pointing consumers to DCP’s website on safe storage and disposal, and, on and after January 1, 2024, a fluorescent orange sticker or label on each container of an opioid or Schedule II, III, IV, or V controlled substance, in black ink: “DANGER TO CHILDREN / KEEP OUT OF REACH.” That sticker is not a take-back registration, but exam stems like to park it next to a returned opioid.

Realistic Connecticut scenario

A patient in Danbury brings back an unopened manufacturer bottle of lisinopril and a half-full oxycodone vial “for credit and restock, and please throw the rest away in your trash.” The lisinopril does not go back on the shelf. If the pharmacy is an authorized collector, the patient places both containers into the receptacle; the technician does not count the oxycodone onto the perpetual CII log. If the pharmacy is not a collector, the pharmacist refuses to take possession over the counter for restock or for the regular trash, points to a collector or law-enforcement box, and may offer § 20-633m deactivation information for the opioid. The same week, the pharmacy’s own expired stock is staged for a reverse distributor pickup — that tote is inventory, documented under DEA destruction rules, and it does not go into the patient drop box (§ 20-576a-2(g)). Across town, a hospital pharmacist relabels an unopened tamper-evident saline-flush-incompatible antibiotic minibag from a discontinued inpatient order to another inpatient under § 20-621. That hospital step is not a template for the Danbury community counter.

Official anchors

• CGS § 20-576a — unused prescription drugs at pharmacies; RCSA 20-576a — authorized collector, receptacle, liner disposal, reverse distributors.
• CGS § 20-621 — hospital/nursing-home unopened parenteral relabeling.
• 21 CFR Part 1317 — DEA disposal, collectors, mail-back, take-back events.
• CGS § 20-636 — storage/disposal sign and opioid/CII–V warning sticker; CGS § 20-633m — optional opioid deactivation information.